5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-8-amine

Catalog No. :
ACSBMN018
CAS No. :
2223046-91-9
Molecular Formula :
C15H19BN2O2
Molecular Weight :
270.14

IUPAC Name:5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-8-amine

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-8-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-8-amine
IUPAC Name5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-8-amine
Molecular FormulaC15H19BN2O2
Molecular Weight270.14
SMILESNC1=CC=C(B2OC(C)(C)C(C)(C)O2)C3=C1C=NC=C3
InChI KeyXHEVARFKWIUWFP-UHFFFAOYSA-N
Synonym8-Isoquinolinamine, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-8-amine;8-Amino-isoquinoline-5-boronic acid pinacol ester;5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-8-isoquinolinamine
CAS No.2223046-91-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACSBMN018 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACRCFD713 route compound structure diagram
    ACRCFD71390721-35-0 In Stock
  4. Then
  5. ACSBMN018 route product structure diagram
    ACSBMN0182223046-91-9
Inquiry

2. ACSBMN018 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSBMN018 route product structure diagram
    ACSBMN0182223046-91-9
Inquiry

Comments (0)